Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Beauty Health Co. demonstrated a positive financial trajectory with 4Q23 revenue reaching $96.8 million, surpassing both previous estimates of $95.2 million and $88.0 million, indicating strong demand and effective consumption management. The total systems average selling price (ASP) experienced a notable increase of approximately 20% quarter-over-quarter, rising to $28.8K, which was significantly ahead of prior expectations, reflecting an improved channel mix favoring direct sales. Despite the company's EBITDA guidance being back-end weighted, the strong performance in revenue and ASP suggests robust business fundamentals that position Beauty Health favorably for future growth.

Bears say

Beauty Health's stock outlook is negatively impacted by a significant decline in core delivery system placements, which fell over 30% year-over-year and quarter-over-quarter, totaling 1,210 units, and significantly below expectations. The deceleration in new system placements raises concerns about future consumable sales, which are critical for achieving management's profitability goals in 2024. Additionally, management's sales and adjusted EBITDA guidance for the first quarter of 2024 is notably below prior estimates, creating a reliance on an unprecedented increase in EBITDA margins in the second half of the year to meet full-year targets.

SKIN has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Buy based on their latest research and market trends.

According to 3 analysts, SKIN has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.